Carol Hamilton, MD, MHS
Director, Scientific AffairsAreas of expertise
- Tuberculosis prevention, care and treatment, research and programs
- Infectious diseases
- HIV/AIDS
- TB-HIV co-infection research and programs
- Vaccine-preventable diseases
- Neglected tropical diseases
- Global public health and development
Projects & Resources
-
The global resurgence of tuberculosis (TB) over the past decades has been fueled by emerging drug resistance, co-infection with increasingly prevalent HIV and decreasing investments in public health systems.
-
FHI 360 is a member of the Tuberculosis Trials Consortium (TBTC), which conducts clinical, laboratory and epidemiologic research for the diagnosis, clinical management and prevention of TB infection and disease.
-
September 2012 — These tools were developed under TB CAP and TB CARE 1 core-funded projects.
-
HIV infection is the strongest risk factor for a person to develop tuberculosis (TB), and TB is responsible for over a quarter of all AIDS-related deaths worldwide.
-
September 2011 — Providing isoniazid to prevent tuberculosis among people living with HIV is a proven, internationally recommended strategy that has been effectively implemented in low-resource settings.
Published Research
-
Developing a framework for evaluating ethical outcomes of good participatory practices in TB clinical drug trials
MacQueen KM, Eley NT, Frick M, Mingote LR, Chou A, Seidel SS, Hannah S, Hamilton C
J Empir Res Hum Res Ethics 2016 Jul; 11(3): 203-13. [Journal Impact Factor: 1.146]
With the growing acceptance of community engagement and participatory strategies in clinical research, evaluation of the benefits and burdens are needed. Working with global tuberculosis (TB) stakeholders, the authors developed a theory of change evaluation framework for the Good Participatory Practice Guidelines for TB Drug Trials. The framework is a first step in systematically evaluating participatory research in clinical trials.